Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 17/20 | 0.64 |
| ▸ | MTNR1B | P49286 | 16/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6077264 | 0.82 | MTNR1A (0.75) | MTNR1AMTNR1BCYP1A2CYP3A4HPGD | |
| SCHEMBL9302251 | 0.82 | MTNR1A (0.77) | MTNR1AMTNR1BCYP1A2CYP3A4HPGD | |
| Luzindole SCHEMBL4869000 | 0.78 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2CYP3A4HPGD | |
| SCHEMBL6076572 | 0.77 | MTNR1A (0.54) | MTNR1AMTNR1BCYP1A2CYP3A4HPGD | |
| SCHEMBL5348439 | 0.77 | MTNR1A (0.56) | MTNR1AMTNR1BCYP1A2CYP3A4HPGD | |
| SCHEMBL9304093 | 0.75 | MTNR1A (0.75) | MTNR1AMTNR1BCYP1A2CYP3A4HPGD | |
| SCHEMBL9304037 | 0.73 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2CYP3A4HPGD | |
| SCHEMBL9401161 | 0.70 | MTNR1A (0.84) | MTNR1AMTNR1BCYP1A2CYP3A4HPGD | |
| Luzindole SCHEMBL9118261 | 0.70 | MEN1 (0.81) | MTNR1AMTNR1BCYP1A2CYP3A4HPGD | |
| SCHEMBL6076899 | 0.70 | MTNR1A (0.45) | MTNR1AMTNR1BCYP1A2CYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123529-A1 | Substituted biphenyl compounds | LES LABORATOIRES SERVIER (FR) | 2007-05-31 | — | — | US | disclosed |
| US-7161035-B2 | Substituted biphenyl derivatives, method for preparing same and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2007-01-09 | — | — | US | disclosed |
| CN-1233621-C | Substituted biphenyl derivatives, method for preparing same and pharmaceutical compositions containing same | SERVIER LAB (FR) | 2005-12-28 | — | — | CN | disclosed |
| US-20040014969-A1 | Substituted biphenyl derivatives, method for preparing same and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2004-01-22 | — | — | US | disclosed |
| CN-1457337-A | Substituted biphenyl derivatives, method for preparing same and pharmaceutical compositions containing same | SERVIER LAB (FR) | 2003-11-19 | — | — | CN | disclosed |
| CN-1128142-C | Novel substituted dipolymer compounds, prepn. method therefor, pharmaceutical compositions contg. same | ADIR (FR) | 2003-11-19 | — | — | CN | disclosed |
| EP-1057826-B1 | Substituted dimeric carboxamide derivatives, method for preparing them, and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-04-16 | — | — | EP | disclosed |
| US-6310074-B1 | TREATING MELATONINERGIC DISORDERS | ADIR ET COMPAGNIE (FR) | 2001-10-30 | — | — | US | disclosed |
| EP-1057826-A1 | Substituted dimeric carboxamide derivatives, method for preparing them, and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2000-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014969-A1 | Substituted biphenyl derivatives, method for preparing same and pharmaceutical compositions containing same | MTNR1A, MTNR1B, MC2R | MTNR1A 1/4885MTNR1B 2/4885CYP1A2 106/4885 |
| US-20070123529-A1 | Substituted biphenyl compounds | MTNR1A, MTNR1B, CNR1 | MTNR1A 1/4885MTNR1B 2/4885CYP1A2 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.